Trials / Completed
CompletedNCT00638755
The Effect of Nasal Carbon Dioxide (CO2) on Nasal Congestion in Subjects With Perennial Allergic Rhinitis
A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study to Evaluate the Effect of Nasal Carbon Dioxide on Nasal Congestion Via Acoustic Rhinometry in Subjects With Perennial Allergic Rhinitis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Capnia, Inc. · Industry
- Sex
- All
- Age
- 19 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the effect of nasal CO2 on nasal congestion and other symptoms related to Perennial Allergic Rhinitis.
Detailed description
A randomized study to evaluated the safety and effect of nasal carbon dioxide on nasal congestion using acoustic rhinometry in subjects with perennial allergic rhinitis. The acoustic rhinometry is an instrument that will be used to assess the levels of the nasal congestion in each subject. Approximately 20 men and women ages 19-65 years old who have a history consistent with perennial allergic rhinitis requiring pharmacology for at least 2 years and meet all other eligibility criteria will be enrolled in this study. There will be six (6) visits to the clinic. There will be a screening visit, four (4) treatment visits, and an end of study visit. A subject's participation in the study may last up to 58 days. There will be four different doses given in this study. Each subject will receive 3 different doses of the study drug and one dose of the placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nasal Carbon Dioxide | Nasal Carbon Dioxide |
| DRUG | Nasal Carbon Dioxide | Nasal Carbon Dioxide |
| DRUG | Nasal Carbon Dioxide | Nasal Carbon Dioxide |
| DRUG | Nasal Carbon Dioxide | Nasal Carbon Dioxide |
Timeline
- Start date
- 2008-02-01
- Primary completion
- 2008-05-01
- Completion
- 2008-07-01
- First posted
- 2008-03-19
- Last updated
- 2010-08-19
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00638755. Inclusion in this directory is not an endorsement.